Comprehensive analysis of marker gene detection and computed tomography for the diagnosis of human lung cancer

Cheng,Min; Sun,Xiaosong; Liu,Guifeng; Cheng,Kailiang; Lv,Zhongwen; Sun,Changjiang; Xiu,Dianhui; Liu,Lin

doi:10.3892/ol.2018.9211

Comprehensive analysis of marker gene detection and computed tomography for the diagnosis of human lung cancer

Authors:
- Min Cheng
- Xiaosong Sun
- Guifeng Liu
- Kailiang Cheng
- Zhongwen Lv
- Changjiang Sun
- Dianhui Xiu
- Lin Liu
View Affiliations

Affiliations: Department of Radiology, Jilin University, China Japan Union Hospital, Changchun, Jilin 130033, P.R. China, Department of Head and Neck Surgery, Jilin Cancer Hospital, Changchun, Jilin 130000, P.R. China
Published online on: July 25, 2018 https://doi.org/10.3892/ol.2018.9211
Pages: 4400-4406
Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small cell lung cancer (NSCLC) is one of leading causes of cancer‑associated mortality, with a high number of cases caused by metastasis. The early diagnosis of cancer contributes to the successful treatment of patients with lung cancer. The aim of the present study was to analyze the efficacy of marker gene detection and computed tomography (CT) in diagnosing human lung cancer. Lung cancer marker genes, including carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), tissue polypeptide antigen (TPA), pro‑gastrin‑releasing peptide (ProGRB), cytokeratin fragment 21‑1 (Cyfra21‑1) and neuron‑specific enolase (NSE), were analyzed in patients with lung cancer. The tumor size was evaluated using CT, and the association between lung serum levels of marker gene protein expression and tumor size was investigated. A total of 328 patients with lung cancer were identified, including 204 adenocarcinoma, 75 large cell carcinoma and 49 squamous cell carcinoma cases. All patients were indicated to have a high serum level of CEA, CA125, TPA, ProGRB, Cyfra21‑1 and NSE, compared with the normal range. Immunohistochemistry demonstrated higher expression levels of CEA, CA125, TPA, ProGRB, Cyfra21‑1 and NSE in lung tumor tissues, compared with the normal range. Results indicated that CT was able to diagnose tumor size for patients with lung cancer. The CEA and CA125 expression levels were associated with CT‑diagnosed adenocarcinoma tumor size. Large cell carcinoma tumor size was associated with serum levels of CEA, TPA and ProGRB. Results indicated that Cyfra21‑1 and NSE were associated with the squamous cell carcinoma cases, as demonstrated using CT. In conclusion, these results indicated that comprehensive analysis of marker gene detection and CT results may be used to diagnose human lung cancer.

View Figures

View References

1	Paleiron N, Bylicki O, André M, Rivière E, Grassin F, Robinet G and Chouaïd C: Targeted therapy for localized non-small-cell lung cancer: A review. Onco Targets Ther. 9:4099–4104. 2016. View Article : Google Scholar : PubMed/NCBI
2	Li SJ, Huang J, Zhou XD, Zhang WB, Lai YT and Che GW: Clinicopathological and prognostic significance of Oct-4 expression in patients with non-small cell lung cancer: A systematic review and meta-analysis. J Thorac Dis. 8:1587–1600. 2016. View Article : Google Scholar : PubMed/NCBI
3	Aokage K, Yoshida J, Hishida T, Tsuboi M, Saji H, Okada M, Suzuki K, Watanabe S and Asamura H: Limited resection for early-stage non-small cell lung cancer as function-preserving radical surgery: A review. Jpn J Clin Oncol. 47:7–11. 2017. View Article : Google Scholar : PubMed/NCBI
4	Brody H: Lung cancer. Nature. 513:S12014. View Article : Google Scholar : PubMed/NCBI
5	Moro-Sibilot D, Smit E, de Castro Carpeño J, Lesniewski-Kmak K, Aerts JG, Villatoro R, Kraaij K, Nacerddine K, Dyachkova Y, Smith KT, et al: Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study. Lung Cancer. 90:427–432. 2015. View Article : Google Scholar : PubMed/NCBI
6	Barnett SA, Downey RJ, Zheng J, Plourde G, Shen R, Chaft J, Akhurst T, Park BJ and Rusch VW: Utility of routine PET imaging to predict response and survival after induction therapy for non-small cell lung cancer. Ann Thorac Surg. 101:1052–1059. 2016. View Article : Google Scholar : PubMed/NCBI
7	Loganadane G, Martinetti F, Mercier O, Krhili S, Riet FG, Mbagui R, To H, Le Péchoux C and Levy A: Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: A critical literature review of predictive factors of relapse. Cancer Treat Rev. 50:240–246. 2016. View Article : Google Scholar : PubMed/NCBI
8	Kim JO, Davis F, Butts C and Winget M: Waiting time intervals for non-small cell lung cancer diagnosis and treatment in alberta: Quantification of intervals and identification of risk factors associated with delays. Clin Oncol (R Coll Radiol). 28:750–759. 2016. View Article : Google Scholar : PubMed/NCBI
9	Zheng D and Chen H: Advances in liquid biopsy and its clinical application in the diagnosis and treatment of non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 19:394–398. 2016.(In Chinese). PubMed/NCBI
10	Benitez-Majano S, Fowler H, Maringe C, Di Girolamo C and Rachet B: Deriving stage at diagnosis from multiple population-based sources: Colorectal and lung cancer in England. Br J Cancer. 115:391–400. 2016. View Article : Google Scholar : PubMed/NCBI
11	Sheu CC, Chang MY, Chang HC, Tsai JR, Lin SR, Chang SJ, Hwang JJ, Huang MS and Chong IW: Combined detection of CEA, CK-19 and c-met mRNAs in peripheral blood: A highly sensitive panel for potential molecular diagnosis of non-small cell lung cancer. Oncology. 70:203–211. 2006. View Article : Google Scholar : PubMed/NCBI
12	Chanvorachote P, Luanpitpong S, Chunhacha P, Promden W and Sriuranpong V: Expression of CA125 and cisplatin susceptibility of pleural effusion-derived human lung cancer cells from a Thai patient. Oncol Lett. 4:252–256. 2012. View Article : Google Scholar : PubMed/NCBI
13	Passowicz-Muszyńska E, Gisterek I, Marciniak M, Kornafel J, Kolodziej J and Jankowska R: Tumor markers TPA and Cyfra 21.1 in patients with non-small cell lung cancer after surgery and chemotherapy. Pol Merkur Lekarski. 13:294–297. 2002.(In Polish). PubMed/NCBI
14	Tang JH, Zhang XL, Zhang ZH, Wang R, Zhang HM, Zhang ZL, Wang JH and Ren WD: Diagnostic value of tumor marker pro-gastrin-releasing peptide in patients with small cell lung cancer: A systematic review. Chin Med J (Engl). 124:1563–1568. 2011.PubMed/NCBI
15	Lazarev SM, Massard ZH, Reshetov AV, Nikolaev GV, Volgin GN, Osipov EV, Lomteva EIu, Nokhrin AV and Kakysheva OE: Role of biological tumor markers CEA, Cyfra-21, NSE, TU M2-PK in diagnosis and treatment of lung cancer. Vestn Khir Im I I Grek. 169:39–43. 2010.(In Russian). PubMed/NCBI
16	Raz DJ, Wu GX, Consunji M, Nelson RA, Kim H, Sun CL, Sun V and Kim JY: The effect of primary care physician knowledge of lung cancer screening guidelines on perceptions and utilization of low-dose computed tomography. Clin Lung Cancer. 19:51–57. 2018. View Article : Google Scholar : PubMed/NCBI
17	Kawakami W, Takemura A, Yokoyama K, Nakajima K, Yokoyama S and Koshida K: The use of positron emission tomography/computed tomography imaging in radiation therapy: A phantom study for setting internal target volume of biological target volume. Radiat Oncol. 10:12015. View Article : Google Scholar : PubMed/NCBI
18	Edge SB and Compton CC: The American joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Hayes AF and Rockwood NJ: Regression-based statistical mediation and moderation analysis in clinical research: Observations, recommendations, and implementation. Behav Res Ther. 98:39–57. 2017. View Article : Google Scholar : PubMed/NCBI
21	Fenton-Ambrose L and Kazerooni EA: Preventative care: Lung-cancer screens now worth the cost. Nature. 514:352014. View Article : Google Scholar : PubMed/NCBI
22	Herth F, Kirsch CM and Stoelben E: Diagnosis of non-small-cell lung carcinoma (NSCLC). Onkologie. 29(Suppl 2): S3–S6. 2006.(In German). View Article : Google Scholar
23	Fiala O, Pesek M, Finek J, Svaton M, Sorejs O, Bortlicek Z, Kucera R and Topolcan O: Prognostic significance of serum tumor markers in patients with advanced-stage NSCLC treated with pemetrexed-based chemotherapy. Anticancer Res. 36:461–466. 2016.PubMed/NCBI
24	Barrio-Muñoz M1, Abad-Gairín C, Amengual-Guedán JM and Prats-López J: Diagnosis of prostate cancer by analyzing oxidative stress in human seminal plasma: Developing unsophisticated tools for noninvasive prostate cancer diagnosis. Eur J Cancer Prev. 25:518–523. 2016. View Article : Google Scholar : PubMed/NCBI
25	Yang L, Wang J, Li J, Zhang H, Guo S, Yan M, Zhu Z, Lan B, Ding Y, Xu M, et al: Identification of serum biomarkers for gastric cancer diagnosis using a human proteome microarray. Mol Cell Proteomics. 15:614–623. 2016. View Article : Google Scholar : PubMed/NCBI
26	Zhu Y, Guo M, Zhang L, Xu T, Wang L and Xu G: Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer. Oncol Rep. 35:454–462. 2016. View Article : Google Scholar : PubMed/NCBI
27	Li S, Zheng Q, Ma Y, Wang Y, Feng Y, Zhao B and Yang Y: Implications of false negative and false positive diagnosis in lymph node staging of NSCLC by means of ¹⁸F-FDG PET/CT. PLoS One. 8:e785522013. View Article : Google Scholar : PubMed/NCBI
28	Kim HS, Lee KS, Ohno Y, van Beek EJ and Biederer J: PET/CT versus MRI for diagnosis, staging, and follow-up of lung cancer. J Magn Reson Imaging. 42:247–260. 2015. View Article : Google Scholar : PubMed/NCBI
29	Takahashi Y, Takashima S, Hakucho T, Miyake C, Morimoto D, Jiang BH, Numasaki H, Tomita Y, Nakanishi K and Higashiyama M: Diagnosis of regional node metastases in lung cancer with computer-aided 3D measurement of the volume and CT-attenuation values of lymph nodes. Acad Radiol. 20:740–745. 2013. View Article : Google Scholar : PubMed/NCBI
30	Yang YJ, Cheng DY, Fang X and Li XX: The clinical diagnosis value of fibro-optic bronchoscope examination combined with tumor marker determination to lung cancer. Sichuan Da Xue Xue Bao Yi Xue Ban. 38:312–315. 2007.(In Chinese). PubMed/NCBI
31	Shi GL, Hu XL, Yue SD and Song CX: The value of serum tumor marker in the diagnosis of lung cancer. Zhonghua Zhong Liu Za Zhi. 27:299–301. 2005.PubMed/NCBI
32	Pollán M, Varela G, Torres A, de la Torre M, Ludeña MD, Ortega MD, Pac J, Freixenet J, Gómez G, Sebastián F, et al: Clinical value of p53, c-erbB-2, CEA and CA125 regarding relapse, metastasis and death in resectable non-small cell lung cancer. Int J Cancer. 107:781–790. 2003. View Article : Google Scholar : PubMed/NCBI
33	Wang P, Piao Y, Zhang X, Li W and Hao X: The concentration of CYFRA 21-1, NSE and CEA in cerebro-spinal fluid can be useful indicators for diagnosis of meningeal carcinomatosis of lung cancer. Cancer Biomark. 13:123–130. 2013. View Article : Google Scholar : PubMed/NCBI
34	Wang H and Qian J: Serum pro-gastrin-releasing peptide in diagnosis of small cell lung cancer: A meta-analysis. J Cancer Res Ther. 12 Suppl:C260–C263. 2016. View Article : Google Scholar : PubMed/NCBI